This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Arena Gets Small Dowry for Obesity Drug

SAN DIEGO ( TheStreet) -- Arena Pharmaceuticals (ARNA) is getting just $50 million upfront from the Japanese drug maker Eisai in exchange for U.S. marketing rights to the company's experimental obesity drug lorcaserin.

A $50 million dowry is pretty chincy given the blockbuster sales potential for weight-loss drugs. Eisai and Arena might be engaged but it seems like they've decided to wait before sleeping together.

The U.S. Food and Drug Administration is already reviewing lorcaserin, with an approval decision expected on Oct. 22. At this advanced stage, Eisai would have easily paid well over $100 million in upfront rights for lorcaserin if the company were confident in the drug's approval and commercial potential. Instead, Eisai is holding off, willing to pay Arena big bucks -- upwards of $1 billion or more -- only if lorcaserin is approved and generates top-tier sales, according to terms of the agreement announced Thursday.

Still, Arena deserves kudos for being the first of the obesity drug players to land a marketing partner. Investors have been watching closely to see if any the large drug companies would latch onto one of these weight-loss drugs now making their way through the U.S. Food and Drug Administration review process. Arena won this stage of the competition, while rivals Vivus (VVUS) and Orexigen Therapeutics (OREX) are still single.

The chief concern with lorcaserin is that patients treated with the drug in two pivotal phase III studies didn't lose much weight -- a little more than 3% on a placebo adjusted basis. The biggest positive in lorcaserin's corner is the drug's safety and tolerability, which appear better than its rivals.

An FDA advisory panel will review lorcaserin on Sept. 16.

Investors are reacting to Arena's partnering announcement Thursday with relatively cool detachment, likely due to Eisai's small upfront payment. Arena shares are up 62 cents, or 20%, to $3.69 in pre-market trading. The stock closed Wednesday at $3.07.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,220.76 +63.91 0.37%
S&P 500 2,009.69 +8.12 0.41%
NASDAQ 4,584.8890 +22.70 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs